Table 3.
Clinical studies investigating the role of CRP in predicting cancer patient outcomes.
| Reference | Cancer type | Measurements | # of patients | Range cutoffs | Multivariate HR (OS) | Time of measurement |
|---|---|---|---|---|---|---|
| Szkandera et al. (93) | Pancreatic | CRP | 474 | CRP > 4.5 mg/L | 1.6, p = 0.005 | Diagnosis |
| Lamb et al. (94) | Clear cell RCC | mGPS | 169 | mGPSa | 4.59, p < 0.001 | Pretreatment |
| Komai et al. (95) | RCC | CRP | 101 | CRP > 5 mg/L | CSS—2.7, p = 0.012 | Presurgery |
| Karakiewicz et al. (96) | RCC | CRP | 313 | CRP > 23 mg/L | CSS—11, p = 0.002 | Preoperative |
| Crumley et al. (97) | Gastric | CRP, alb | 217 | CRP > 10 mg/L, alb < 35 g/L | Alb—NS, CRP—2.37, p < 0.001 | Pretreatment |
| Tatokoro et al. (98) | RCC | CRP | 40 | CRP > 5 mg/L | CSS—4.84 (non-normalized postsurgery), p < 0.0001 | Pre/postoperative |
| Shimada et al. (99) | Esophageal squamous cell carcinoma | CRP | 150 | CRP > 1 mg/L | 1.68, p = 0.049 | Preoperative |
| Shiu et al. (100) | Colorectal | CRP | 212 | CRP > 5 mg/L | CSS—6.51, p = 0.016 | Preoperative |
aMGPS = 1 if CRP > 10 mg/mL, mGPS = 2 if CRP > 10 mg/L and albumin < 35 g/L, mGPS = 0 if both CRP and albumin are normal.
alb, albumin; CRP, C-reactive protein; CSS, cancer-specific survival; OS, overall survival; RCC, renal cell carcinoma.